Background: Randomized controlled trials demonstrated lowering risks of cardiovascular events with sodiumglucose cotransporter-2 (SGLT2) inhibitors in patients with type 2 diabetes mellitus (T2DM) and high cardiovascular risk. We analyzed the effects of cardiovascular function on SGLT2 inhibitors compared with dipeptidyl peptidase-4 (DPP4) inhibitors in T2DM with atherosclerotic cardiovascular disease (ASCVD) or heart failure (HF). Methods: This is a retrospective, observational, single center study. Data from 89 patients with ASCVD or HF from January 2015 to February 2018 were analyzed regarding the effect of SGLT2 inhibitors and DPP4 inhibitors. Cardiovascular function was assessed by 2-D echocardiography and N-terminal prohormone of brain natriuretic peptide (NT-pro BNP). Results: A total of 89 patients with T2DM were considered in two groups of SGLT2 inhibitors (n=41) and DPP4 inhibitors (n=48). The mean follow-up period was 2 years, with a total of 89 patient-years. Despite no significant change in systolic function, SGLT2 inhibitors improved cardiovascular function, as demonstrated by a reduced left ventricular ejection fraction less than 40%, ratio of mitral peak velocity of early filling velocity to early diastolic mitral annular velocity, ratio of early to late ventricular filling velocities, and NT-pro BNP compared with the DPP4 inhibitor group. Conclusion: SGLT2 inhibitors improve cardiovascular function in T2DM with coronary artery disease compared to DPP4 inhibitors.
INTRODUCTION
Prevalence of type 2 diabetes mellitus (T2DM) has been increasing, and T2DM has become a leading cause of cardiovascular mortality in the last decades. 1 In Korea, patients with T2DM also have higher risk of cardiovascular diseases. 2 Patients with DM have a higher rate of obesity than non-diabetic patients, indicating that cardiovascular metabolic risk factors may be higher in the T2DM group. 2, 3 Hyperglycemia is significantly related to cardiovascular mortality and morbidity, including myocardial infarction (MI), heart failure (HF), stroke, and hospitalization. 4 Antihyperglycemic tors in patients with cardiovascular diseases. 7, 8 Some SGLT2 inhibitors have been reported to reduce major adverse cardiovascular events, cardiovascular death, and hospitalization for HF. 3, 7, 8 However, the mechanism of SGLT2 inhibitor benefits, including reduction of morbidity, mortality, and HF aggravation, remains unclear.
Regarding cardiovascular diseases, the effects of dipeptidyl peptidase-4 (DPP4) inhibitors were not inferior to those of other antidiabetic drugs. [8] [9] [10] A few studies of the effects of SGLT2 inhibitors have been performed in Korea. One report indicated that SGLT2
inhibitors reduced the rate of hospitalization from HF. 11 For patients with T2DM and coronary artery disease, few studies have been performed to investigate changes in cardiovascular markers with SLGT2 inhibitors compared with DPP4 inhibitors. Discussion is needed regarding differences in cardiovascular function related to SGLT2 inhibitors and DPP4 inhibitors in patients with T2DM and coronary artery disease.
The purpose of this study was to investigate whether SGLT2 inhibitors have positive effects on patients with T2DM and coronary artery disease. SGLT2 inhibitors can induce changes in cardiovascular markers, which may lead to differences between groups treated with SGLT2 inhibitors versus DPP4 inhibitors. Differences between these two groups were investigated by comparing cardiovas- 
METHODS

Study design
This study was retrospective and observational. A total of 444 patients with DM were excluded due to use of other Figure 1 . Flowchart of patient selection and grouping. All 822 patients had underwent percutaneous coronary intervention or coronary artery bypass graft and had type 2 diabetes mellitus (T2DM). Four hundred forty-four patients were excluded because they took antidiabetic medications other than sodium-glucose cotransporter-2 (SGLT2) inhibitors or dipeptidyl peptidase-4 (DPP4) inhibitors. Two hundred eighty-nine of 378 patients were excluded for age or estimated glomerular filtration rate (eGFR). Eightynine patients were distributed to SGLT2 inhibitor or DPP4 inhibitor groups. 
RESULTS
The 89 patients were divided into two groups (SGLT2 inhibitors vs DPP4 inhibitors). In the SGLT2 inhibitors group, mean baseline Table 2) . No significant difference in LVEF was observed between these two groups (Fig. 2) . Subgroup analysis was performed based on degree of LVEF ( < 40%, 40%-50%, ≥ 50%) and E/e' ( < 13, ≥ 13). The SGLT2 inhibitor group had improved LV dysfunction, especially in the reduced LVEF group (LVEF < 40%; -9.57 ± 8.39, P = 0.035). Diastolic dysfunction markers (E/e' , 6.54 ± 2.95) and NT-pro BNP were also improved in the SGLT2 inhibitor group (P = 0.008), especially in the E/e' ≥ 13 subgroup (Table 3 ). The DPP4 inhibitor group had a higher rate of rehospitalization (22% vs. 55.1%, P = 0.002). The major cause of hospitalization in both groups was coronary artery disease (data not shown). While patients in the SGLT2 inhibitor group had reduced body weight or BMI, there was no difference in BMI 
DISCUSSION
This study was designed to assess differences between patients with T2DM and CAD treated with SGLT2 inhibitors or DPP4 inhibitors. After PCI or CABG was performed, SGLT2 inhibitors or DPP4 inhibitors were prescribed to two different groups. Patient distribution (SGLT2 inhibitors vs DPP4 inhibitors) was similar to that of the EMPA-REG trial. 7 Our study included patients with CAD but not cerebrovascular diseases. Conversely, the EMPA-REG trial included patients with CAD and cerebrovascular diseases.
BP (systole, diastole), NT-pro BNP, systolic cardiac functions (LVEF), and diastolic cardiac function marker (E/e') were significantly reduced, especially in the SGLT2 inhibitors group. No sig- Values are presented as mean± standard deviation. Systolic function (ejection fraction), especially < 40 group, improved significantly in SGLT2 inhibitor group (P= 0.035). Diastolic dysfunction (E/e'), especially ≥ 13 group, improved in SGLT2 inhibitor group (P= 0.008). *P< 0.05, statistically significant difference. E/e', ratio of mitral peak velocity of early filling (E) to early diastolic mitral annular velocity (E'); SGLT2, sodium-glucose cotransporter-2; DPP4, dipeptidyl peptidase-4. lower risk of cardiovascular diseases and lower risks of mortality or morbidity, especially hospitalization. 9 Our study showed that SGLT2 inhibitors reduced the hospitalization rate. The multicenter randomized EMPA-REG trial suggested that empagliflozin reduced the relative risks of HF hospitalization, cardiovascular death, and kidney disease progression rate. 7, 9 The CANVAS trial published that canagliflozin lowered the risk of cardiovascular events and decreased the deterioration rate of renal clearance. 12 In the CVD-RE-AL study, the SGLT2 inhibitor group had a lower rate of hospital- The "thrifty substrate" or "fuel" hypothesis was independently proposed by Ferrannini et al. 19 and Mudaliar et al. 20 They both hypothesized that removal of large amounts of glucose from the body and subsequent reduction of the insulin/glucagon ratio associated with empagliflozin treatment may boost lipid mobilization and oxidation in the liver to stimulate ketogenesis. 19, 20 The resulting metabolic condition, characterized by a mildly hyperketonemic state akin to prolonged fasting, leads to avid myocardial uptake of β-hydroxybutyrate, which competes with fatty acid oxidation. This substrate shift is considered cardioprotective because oxidation of ketone bodies is more metabolically efficient and may act as a "superfuel" for the heart. 19 No differences in body weight change were observed between the SGLT2 inhibitor group and DPP4 inhibitor group in this study.
Although performed at the same center as our study, Cho et al. 21 reported that SGLT2 inhibitors significantly reduced body weight.
This discrepancy might be because patients treated with DPP4 inhibitors underwent improved life style modifications after undergoing surgery or PCI. The discrepancy could also be a limitation of this retrospective study.
There are several limitations. First, there were discrepancies in baseline characteristics of the two groups. SGLT2 inhibitors are known to induce ketoacidosis. Because the study was retrospective, it was impossible to know the ketone body level before treatment with SGLT2 inhibitor or DPP4 inhibitor was initiated. Therefore, changes in ketone bodies were not evaluated. Second, this study was performed at a single center with relatively few patients available for analysis. While there were initially 822 enrolled patients, the SGLT2 inhibitor taken group included merely 41 patients and the DPP4 inhibitor group included 48 patients. Few patients had data available for EF (LV systolic function) or E/e' (diastolic function). Third, total observation time (38 months) after launching new drugs such as empagliflozin and dapagliflozin was insufficient to prove potential cardiovascular benefits for patients with coronary diseases.
SGLT2 inhibitors improved BP, hospitalization for CAD or HF, and cardiovascular function (NT-pro BNP, E/e' , E/A ratio in the HFrEF group) compared with DPP4 inhibitors. We suggest that SGLT2 inhibitors improve cardiovascular function in patients with T2DM and coronary artery disease compared to DPP4 inhibitors.
The cardiovascular effects of SLGT2 inhibitors should be further evaluated in a large scale prospective study in Korea.
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